Coronavirus disease 2019 (COVID-19) and QTc prolongation.
Identifieur interne : 000169 ( Main/Corpus ); précédent : 000168; suivant : 000170Coronavirus disease 2019 (COVID-19) and QTc prolongation.
Auteurs : Khalid Changal ; David Paternite ; Sean Mack ; Spiro Veria ; Rehana Bashir ; Mitra Patel ; Ronak Soni ; Muhammad Ali ; Tanveer Mir ; Mujeeb Sheikh ; P Kasi RamanathanSource :
- BMC cardiovascular disorders [ 1471-2261 ] ; 2021.
English descriptors
- KwdEn :
- Age Factors (MeSH), Aged (MeSH), COVID-19 (classification), COVID-19 (complications), COVID-19 (drug therapy), COVID-19 (epidemiology), COVID-19 (physiopathology), COVID-19 (therapy), Cardiovascular Diseases (epidemiology), Comorbidity (MeSH), Correlation of Data (MeSH), Electrocardiography (methods), Electrocardiography (statistics & numerical data), Female (MeSH), Humans (MeSH), Long QT Syndrome (diagnosis), Long QT Syndrome (epidemiology), Long QT Syndrome (etiology), Male (MeSH), Middle Aged (MeSH), Outcome and Process Assessment, Health Care (MeSH), Renal Insufficiency, Chronic (epidemiology), Risk Assessment (methods), SARS-CoV-2 (isolation & purification), Survival Analysis (MeSH), United States (epidemiology).
- MESH :
- geographic , epidemiology : United States.
- classification : COVID-19.
- complications : COVID-19.
- diagnosis : Long QT Syndrome.
- drug therapy : COVID-19.
- epidemiology : COVID-19, Cardiovascular Diseases, Long QT Syndrome, Renal Insufficiency, Chronic.
- etiology : Long QT Syndrome.
- isolation & purification : SARS-CoV-2.
- methods : Electrocardiography, Risk Assessment.
- physiopathology : COVID-19.
- statistics & numerical data : Electrocardiography.
- therapy : COVID-19.
- Age Factors, Aged, Comorbidity, Correlation of Data, Female, Humans, Male, Middle Aged, Outcome and Process Assessment, Health Care, Survival Analysis.
Abstract
INTRODUCTION
The cause-and-effect relationship of QTc prolongation in Coronavirus disease 2019 (COVID-19) patients has not been studied well.
OBJECTIVE
We attempt to better understand the relationship of QTc prolongation in COVID-19 patients in this study.
METHODS
This is a retrospective, hospital-based, observational study. All patients with normal baseline QTc interval who were hospitalized with the diagnosis of COVID-19 infection at two hospitals in Ohio, USA were included in this study.
RESULTS
Sixty-nine patients had QTc prolongation, and 210 patients continued to have normal QTc during hospitalization. The baseline QTc intervals were comparable in the two groups. Patients with QTc prolongation were older (mean age 67 vs. 60, P 0.003), more likely to have underlying cardiovascular disease (48% versus 26%, P 0.001), ischemic heart disease (29% versus 17%, P 0.026), congestive heart failure with preserved ejection fraction (16% versus 8%, P 0.042), chronic kidney disease (23% versus 10%, P 0.005), and end-stage renal disease (12% versus 1%, P < 0.001). Patients with QTc prolongation were more likely to have received hydroxychloroquine (75% versus 59%, P 0.018), azithromycin (18% vs. 14%, P 0.034), a combination of hydroxychloroquine and azithromycin (29% vs 7%, P < 0.001), more than 1 QT prolonging agents (59% vs. 32%, P < 0.001). Patients who were on angiotensin-converting enzyme inhibitors (ACEi) were less likely to develop QTc prolongation (11% versus 26%, P 0.014). QTc prolongation was not associated with increased ventricular arrhythmias or mortality.
CONCLUSION
Older age, ESRD, underlying cardiovascular disease, potential virus mediated cardiac injury, and drugs like hydroxychloroquine/azithromycin, contribute to QTc prolongation in COVID-19 patients. The role of ACEi in preventing QTc prolongation in COVID-19 patients needs to be studied further.
DOI: 10.1186/s12872-021-01963-1
PubMed: 33784966
PubMed Central: PMC8007653
Links to Exploration step
pubmed:33784966Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Coronavirus disease 2019 (COVID-19) and QTc prolongation.</title><author><name sortKey="Changal, Khalid" sort="Changal, Khalid" uniqKey="Changal K" first="Khalid" last="Changal">Khalid Changal</name><affiliation><nlm:affiliation>Cardiovascular Medicine, University of Toledo, Toledo, OH, USA. khalidchangal@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Paternite, David" sort="Paternite, David" uniqKey="Paternite D" first="David" last="Paternite">David Paternite</name><affiliation><nlm:affiliation>University of Toledo College of Medicine and Life Sciences, Toledo, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Mack, Sean" sort="Mack, Sean" uniqKey="Mack S" first="Sean" last="Mack">Sean Mack</name><affiliation><nlm:affiliation>University of Toledo College of Medicine and Life Sciences, Toledo, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Veria, Spiro" sort="Veria, Spiro" uniqKey="Veria S" first="Spiro" last="Veria">Spiro Veria</name><affiliation><nlm:affiliation>University of Toledo College of Medicine and Life Sciences, Toledo, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Bashir, Rehana" sort="Bashir, Rehana" uniqKey="Bashir R" first="Rehana" last="Bashir">Rehana Bashir</name><affiliation><nlm:affiliation>Owen's Community College, Toledo, OH, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Patel, Mitra" sort="Patel, Mitra" uniqKey="Patel M" first="Mitra" last="Patel">Mitra Patel</name><affiliation><nlm:affiliation>University of Toledo College of Medicine and Life Sciences, Toledo, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Soni, Ronak" sort="Soni, Ronak" uniqKey="Soni R" first="Ronak" last="Soni">Ronak Soni</name><affiliation><nlm:affiliation>Cardiovascular Medicine, University of Toledo, Toledo, OH, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Ali, Muhammad" sort="Ali, Muhammad" uniqKey="Ali M" first="Muhammad" last="Ali">Muhammad Ali</name><affiliation><nlm:affiliation>Internal Medicine, University of Toledo, Toledo, OH, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Mir, Tanveer" sort="Mir, Tanveer" uniqKey="Mir T" first="Tanveer" last="Mir">Tanveer Mir</name><affiliation><nlm:affiliation>Internal Medicine, Detroit Medical Center, Wayne State University, Detroit, MI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Sheikh, Mujeeb" sort="Sheikh, Mujeeb" uniqKey="Sheikh M" first="Mujeeb" last="Sheikh">Mujeeb Sheikh</name><affiliation><nlm:affiliation>Department of Cardiovascular Medicine and Interventional Cardiology, Promedica Toledo Hospital, 2109 Hughes Dr, Jobst Tower 3rd, Floor, Toledo, OH, 43606, USA. Smujeeb73@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Ramanathan, P Kasi" sort="Ramanathan, P Kasi" uniqKey="Ramanathan P" first="P Kasi" last="Ramanathan">P Kasi Ramanathan</name><affiliation><nlm:affiliation>Department of Cardiovascular Medicine and Interventional Cardiology, Promedica Toledo Hospital, 2109 Hughes Dr, Jobst Tower 3rd, Floor, Toledo, OH, 43606, USA.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:33784966</idno><idno type="pmid">33784966</idno><idno type="doi">10.1186/s12872-021-01963-1</idno><idno type="pmc">PMC8007653</idno><idno type="wicri:Area/Main/Corpus">000169</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000169</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Coronavirus disease 2019 (COVID-19) and QTc prolongation.</title><author><name sortKey="Changal, Khalid" sort="Changal, Khalid" uniqKey="Changal K" first="Khalid" last="Changal">Khalid Changal</name><affiliation><nlm:affiliation>Cardiovascular Medicine, University of Toledo, Toledo, OH, USA. khalidchangal@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Paternite, David" sort="Paternite, David" uniqKey="Paternite D" first="David" last="Paternite">David Paternite</name><affiliation><nlm:affiliation>University of Toledo College of Medicine and Life Sciences, Toledo, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Mack, Sean" sort="Mack, Sean" uniqKey="Mack S" first="Sean" last="Mack">Sean Mack</name><affiliation><nlm:affiliation>University of Toledo College of Medicine and Life Sciences, Toledo, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Veria, Spiro" sort="Veria, Spiro" uniqKey="Veria S" first="Spiro" last="Veria">Spiro Veria</name><affiliation><nlm:affiliation>University of Toledo College of Medicine and Life Sciences, Toledo, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Bashir, Rehana" sort="Bashir, Rehana" uniqKey="Bashir R" first="Rehana" last="Bashir">Rehana Bashir</name><affiliation><nlm:affiliation>Owen's Community College, Toledo, OH, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Patel, Mitra" sort="Patel, Mitra" uniqKey="Patel M" first="Mitra" last="Patel">Mitra Patel</name><affiliation><nlm:affiliation>University of Toledo College of Medicine and Life Sciences, Toledo, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Soni, Ronak" sort="Soni, Ronak" uniqKey="Soni R" first="Ronak" last="Soni">Ronak Soni</name><affiliation><nlm:affiliation>Cardiovascular Medicine, University of Toledo, Toledo, OH, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Ali, Muhammad" sort="Ali, Muhammad" uniqKey="Ali M" first="Muhammad" last="Ali">Muhammad Ali</name><affiliation><nlm:affiliation>Internal Medicine, University of Toledo, Toledo, OH, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Mir, Tanveer" sort="Mir, Tanveer" uniqKey="Mir T" first="Tanveer" last="Mir">Tanveer Mir</name><affiliation><nlm:affiliation>Internal Medicine, Detroit Medical Center, Wayne State University, Detroit, MI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Sheikh, Mujeeb" sort="Sheikh, Mujeeb" uniqKey="Sheikh M" first="Mujeeb" last="Sheikh">Mujeeb Sheikh</name><affiliation><nlm:affiliation>Department of Cardiovascular Medicine and Interventional Cardiology, Promedica Toledo Hospital, 2109 Hughes Dr, Jobst Tower 3rd, Floor, Toledo, OH, 43606, USA. Smujeeb73@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Ramanathan, P Kasi" sort="Ramanathan, P Kasi" uniqKey="Ramanathan P" first="P Kasi" last="Ramanathan">P Kasi Ramanathan</name><affiliation><nlm:affiliation>Department of Cardiovascular Medicine and Interventional Cardiology, Promedica Toledo Hospital, 2109 Hughes Dr, Jobst Tower 3rd, Floor, Toledo, OH, 43606, USA.</nlm:affiliation></affiliation></author></analytic><series><title level="j">BMC cardiovascular disorders</title><idno type="eISSN">1471-2261</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors (MeSH)</term><term>Aged (MeSH)</term><term>COVID-19 (classification)</term><term>COVID-19 (complications)</term><term>COVID-19 (drug therapy)</term><term>COVID-19 (epidemiology)</term><term>COVID-19 (physiopathology)</term><term>COVID-19 (therapy)</term><term>Cardiovascular Diseases (epidemiology)</term><term>Comorbidity (MeSH)</term><term>Correlation of Data (MeSH)</term><term>Electrocardiography (methods)</term><term>Electrocardiography (statistics & numerical data)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Long QT Syndrome (diagnosis)</term><term>Long QT Syndrome (epidemiology)</term><term>Long QT Syndrome (etiology)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Outcome and Process Assessment, Health Care (MeSH)</term><term>Renal Insufficiency, Chronic (epidemiology)</term><term>Risk Assessment (methods)</term><term>SARS-CoV-2 (isolation & purification)</term><term>Survival Analysis (MeSH)</term><term>United States (epidemiology)</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>United States</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Long QT Syndrome</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>COVID-19</term><term>Cardiovascular Diseases</term><term>Long QT Syndrome</term><term>Renal Insufficiency, Chronic</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Long QT Syndrome</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Electrocardiography</term><term>Risk Assessment</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Electrocardiography</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Age Factors</term><term>Aged</term><term>Comorbidity</term><term>Correlation of Data</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Outcome and Process Assessment, Health Care</term><term>Survival Analysis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>INTRODUCTION</b></p><p>The cause-and-effect relationship of QTc prolongation in Coronavirus disease 2019 (COVID-19) patients has not been studied well.</p></div><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>We attempt to better understand the relationship of QTc prolongation in COVID-19 patients in this study.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>This is a retrospective, hospital-based, observational study. All patients with normal baseline QTc interval who were hospitalized with the diagnosis of COVID-19 infection at two hospitals in Ohio, USA were included in this study.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Sixty-nine patients had QTc prolongation, and 210 patients continued to have normal QTc during hospitalization. The baseline QTc intervals were comparable in the two groups. Patients with QTc prolongation were older (mean age 67 vs. 60, P 0.003), more likely to have underlying cardiovascular disease (48% versus 26%, P 0.001), ischemic heart disease (29% versus 17%, P 0.026), congestive heart failure with preserved ejection fraction (16% versus 8%, P 0.042), chronic kidney disease (23% versus 10%, P 0.005), and end-stage renal disease (12% versus 1%, P < 0.001). Patients with QTc prolongation were more likely to have received hydroxychloroquine (75% versus 59%, P 0.018), azithromycin (18% vs. 14%, P 0.034), a combination of hydroxychloroquine and azithromycin (29% vs 7%, P < 0.001), more than 1 QT prolonging agents (59% vs. 32%, P < 0.001). Patients who were on angiotensin-converting enzyme inhibitors (ACEi) were less likely to develop QTc prolongation (11% versus 26%, P 0.014). QTc prolongation was not associated with increased ventricular arrhythmias or mortality.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>Older age, ESRD, underlying cardiovascular disease, potential virus mediated cardiac injury, and drugs like hydroxychloroquine/azithromycin, contribute to QTc prolongation in COVID-19 patients. The role of ACEi in preventing QTc prolongation in COVID-19 patients needs to be studied further.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33784966</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2261</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>03</Month><Day>30</Day></PubDate></JournalIssue><Title>BMC cardiovascular disorders</Title><ISOAbbreviation>BMC Cardiovasc Disord</ISOAbbreviation></Journal><ArticleTitle>Coronavirus disease 2019 (COVID-19) and QTc prolongation.</ArticleTitle><Pagination><MedlinePgn>158</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12872-021-01963-1</ELocationID><Abstract><AbstractText Label="INTRODUCTION">The cause-and-effect relationship of QTc prolongation in Coronavirus disease 2019 (COVID-19) patients has not been studied well.</AbstractText><AbstractText Label="OBJECTIVE">We attempt to better understand the relationship of QTc prolongation in COVID-19 patients in this study.</AbstractText><AbstractText Label="METHODS">This is a retrospective, hospital-based, observational study. All patients with normal baseline QTc interval who were hospitalized with the diagnosis of COVID-19 infection at two hospitals in Ohio, USA were included in this study.</AbstractText><AbstractText Label="RESULTS">Sixty-nine patients had QTc prolongation, and 210 patients continued to have normal QTc during hospitalization. The baseline QTc intervals were comparable in the two groups. Patients with QTc prolongation were older (mean age 67 vs. 60, P 0.003), more likely to have underlying cardiovascular disease (48% versus 26%, P 0.001), ischemic heart disease (29% versus 17%, P 0.026), congestive heart failure with preserved ejection fraction (16% versus 8%, P 0.042), chronic kidney disease (23% versus 10%, P 0.005), and end-stage renal disease (12% versus 1%, P < 0.001). Patients with QTc prolongation were more likely to have received hydroxychloroquine (75% versus 59%, P 0.018), azithromycin (18% vs. 14%, P 0.034), a combination of hydroxychloroquine and azithromycin (29% vs 7%, P < 0.001), more than 1 QT prolonging agents (59% vs. 32%, P < 0.001). Patients who were on angiotensin-converting enzyme inhibitors (ACEi) were less likely to develop QTc prolongation (11% versus 26%, P 0.014). QTc prolongation was not associated with increased ventricular arrhythmias or mortality.</AbstractText><AbstractText Label="CONCLUSION">Older age, ESRD, underlying cardiovascular disease, potential virus mediated cardiac injury, and drugs like hydroxychloroquine/azithromycin, contribute to QTc prolongation in COVID-19 patients. The role of ACEi in preventing QTc prolongation in COVID-19 patients needs to be studied further.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Changal</LastName><ForeName>Khalid</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Cardiovascular Medicine, University of Toledo, Toledo, OH, USA. khalidchangal@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paternite</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University of Toledo College of Medicine and Life Sciences, Toledo, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mack</LastName><ForeName>Sean</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Toledo College of Medicine and Life Sciences, Toledo, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veria</LastName><ForeName>Spiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Toledo College of Medicine and Life Sciences, Toledo, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bashir</LastName><ForeName>Rehana</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Owen's Community College, Toledo, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Mitra</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Toledo College of Medicine and Life Sciences, Toledo, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soni</LastName><ForeName>Ronak</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cardiovascular Medicine, University of Toledo, Toledo, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Internal Medicine, University of Toledo, Toledo, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mir</LastName><ForeName>Tanveer</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Internal Medicine, Detroit Medical Center, Wayne State University, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheikh</LastName><ForeName>Mujeeb</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine and Interventional Cardiology, Promedica Toledo Hospital, 2109 Hughes Dr, Jobst Tower 3rd, Floor, Toledo, OH, 43606, USA. Smujeeb73@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramanathan</LastName><ForeName>P Kasi</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine and Interventional Cardiology, Promedica Toledo Hospital, 2109 Hughes Dr, Jobst Tower 3rd, Floor, Toledo, OH, 43606, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Cardiovasc Disord</MedlineTA><NlmUniqueID>100968539</NlmUniqueID><ISSNLinking>1471-2261</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078331" MajorTopicYN="N">Correlation of Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004562" MajorTopicYN="Y">Electrocardiography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008133" MajorTopicYN="Y">Long QT Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010043" MajorTopicYN="N">Outcome and Process Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051436" MajorTopicYN="N">Renal Insufficiency, Chronic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">Cardiovascular disease</Keyword><Keyword MajorTopicYN="Y">QT prolongation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>02</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>03</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>31</Day><Hour>5</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33784966</ArticleId><ArticleId IdType="doi">10.1186/s12872-021-01963-1</ArticleId><ArticleId IdType="pii">10.1186/s12872-021-01963-1</ArticleId><ArticleId IdType="pmc">PMC8007653</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>JACC Clin Electrophysiol. 2021 Jan;7(1):16-25</Citation><ArticleIdList><ArticleId IdType="pubmed">33478708</ArticleId></ArticleIdList></Reference><Reference><Citation>Heart Rhythm. 2020 Sep;17(9):1425-1433</Citation><ArticleIdList><ArticleId IdType="pubmed">32407884</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Cell Cardiol. 2016 Aug;97:180-90</Citation><ArticleIdList><ArticleId IdType="pubmed">27210827</ArticleId></ArticleIdList></Reference><Reference><Citation>Travel Med Infect Dis. 2020 Mar - Apr;34:101663</Citation><ArticleIdList><ArticleId IdType="pubmed">32289548</ArticleId></ArticleIdList></Reference><Reference><Citation>Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008662</Citation><ArticleIdList><ArticleId IdType="pubmed">32347743</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetologia. 2020 Nov;63(11):2486-2487</Citation><ArticleIdList><ArticleId IdType="pubmed">32632527</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Care. 2020 Jul;43(7):1408-1415</Citation><ArticleIdList><ArticleId IdType="pubmed">32430456</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Ther. 1999 Sep;6(5):257-61</Citation><ArticleIdList><ArticleId IdType="pubmed">11329107</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cardiol Heart Vasc. 2020 Jun 03;29:100557</Citation><ArticleIdList><ArticleId IdType="pubmed">32550259</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 2005 May 24;111(20):2605-10</Citation><ArticleIdList><ArticleId IdType="pubmed">15897343</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Physiol Renal Physiol. 2009 Feb;296(2):F398-405</Citation><ArticleIdList><ArticleId IdType="pubmed">19004932</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Cardiol. 2009 Mar 17;53(11):982-91</Citation><ArticleIdList><ArticleId IdType="pubmed">19281931</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Metab. 2020 Oct;46(5):403-405</Citation><ArticleIdList><ArticleId IdType="pubmed">32447102</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Heart Assoc. 2020 Sep;9(17):e016948</Citation><ArticleIdList><ArticleId IdType="pubmed">32633594</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Mar 17;323(11):1061-1069</Citation><ArticleIdList><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2020 Apr;92(4):401-402</Citation><ArticleIdList><ArticleId IdType="pubmed">31950516</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Cardiovasc Disord. 2020 Aug 14;20(1):373</Citation><ArticleIdList><ArticleId IdType="pubmed">32799852</ArticleId></ArticleIdList></Reference><Reference><Citation>Basic Clin Pharmacol Toxicol. 2012 Oct;111(4):279-88</Citation><ArticleIdList><ArticleId IdType="pubmed">22626243</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2015 May;125(5):1968-78</Citation><ArticleIdList><ArticleId IdType="pubmed">25844899</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Feb 25;323(8):707-708</Citation><ArticleIdList><ArticleId IdType="pubmed">31971553</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Nov 19;383(21):2030-2040</Citation><ArticleIdList><ArticleId IdType="pubmed">33031652</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cardiovasc Electrophysiol. 2006 Mar;17(3):333-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16643414</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cardiol. 2021 Feb 1;324:242-248</Citation><ArticleIdList><ArticleId IdType="pubmed">32956782</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Infect Dis. 2020 Feb;91:264-266</Citation><ArticleIdList><ArticleId IdType="pubmed">31953166</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Cardiol. 2020 Sep;17(9):543-558</Citation><ArticleIdList><ArticleId IdType="pubmed">32690910</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2020 Jun;26(6):808-809</Citation><ArticleIdList><ArticleId IdType="pubmed">32488217</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiovasc Diabetol. 2020 Jun 11;19(1):76</Citation><ArticleIdList><ArticleId IdType="pubmed">32527257</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000169 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000169 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:33784966
|texte= Coronavirus disease 2019 (COVID-19) and QTc prolongation.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:33784966" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |